General description
INN
Methotrexate
Medicine type
Chemical agent
EML status history
First added in 1977
(TRS
615)
for
Unspecified malignant neoplasms of unspecified sites
Changed in 1997
(TRS
882)
for
Rheumatoid arthritis
Changed in 2011
(TRS
965)
for
Juvenile idiopathic arthritis
Changed in 2015
(TRS
994)
for
Malignant neoplasms of breast
Changed in 2015
(TRS
994)
for
Malignant trophoblastic neoplasms of placenta
Changed in 2015
(TRS
994)
for
Osteosarcoma of bone or articular cartilage of unspecified sites
Changed in 2015
(TRS
994)
for
Lymphoid leukaemia, not elsewhere classified
Changed in 2015
(TRS
994)
for
Acute myeloid leukaemia with recurrent genetic abnormalities
Removed in 2015
(TRS
994)
for
Unspecified malignant neoplasms of unspecified sites
Added in 2021
(TRS
1035)
for
Burkitt lymphoma including Burkitt leukaemia
Changed in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-positive
Changed in 2023
(TRS
1049)
for
Anaplastic large cell lymphoma, ALK-negative
Changed in 2023
(TRS
1049)
for
Langerhans cell histiocytosis
Changed in 2023
(TRS
1049)
for
Psoriasis of unspecified type
Application rejected in 2023
(TRS
1049)
for
Crohn disease site
Application rejected in 2023
(TRS
1049)
for
Psoriatic arthritis
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 1000 mg per 10 mL concentrated injection; 50 mg per 2 mL; 50 mg in vial (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 1000 mg per 10 mL concentrated injection; 50 mg per 2 mL
- Parenteral > General injections > IV: 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection; 50 mg in vial (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
Indications
Malignant neoplasms of breast
Malignant trophoblastic neoplasms of placenta
Osteosarcoma of bone or articular cartilage of unspecified sites
Lymphoid leukaemia, not elsewhere classified
Acute myeloid leukaemia with recurrent genetic abnormalities
Unspecified malignant neoplasms of unspecified sites
Burkitt lymphoma including Burkitt leukaemia
Anaplastic large cell lymphoma, ALK-positive
Anaplastic large cell lymphoma, ALK-negative
Langerhans cell histiocytosis
Section
Disease-modifying anti-rheumatic drugs (DMARDs)
- Oral > Solid > tablet: 2.5 mg (as sodium salt)
Indications
Section
Medicines for juvenile joint diseases
- Oral > Solid > tablet: 2.5 mg (as sodium salt)
Indications
Section
Dermatological medicines > Medicines affecting skin differentiation and proliferation
- Oral > Solid > tablet: 10 mg (as sodium salt); 2.5 mg (as sodium salt)
Indications
Section
Immunomodulators for non-malignant disease
- Parenteral > General injections > SC: pre-filled syringe in multiple strengths
Indications